Page last updated: 2024-12-06

recainam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

recainam: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID53084
CHEMBL ID551786
SCHEMBL ID636093
MeSH IDM0118306

Synonyms (21)

Synonym
recainam
wy-42362
recainam [inn:ban]
n-(2,6-dimethylphenyl)-n'-(3-((1-methylethyl)amino)propyl)urea
urea, n-(2,6-dimethylphenyl)-n'-(3-((1-methylethyl)amino)propyl)-
wy-42,362
wy 42362
recainamum [latin]
CHEMBL551786
1-(2,6-dimethylphenyl)-3-[3-(propan-2-ylamino)propyl]urea
74738-24-2
unii-646kre84zg
recainamum
646kre84zg ,
recainam [inn]
recainam [mart.]
1-(3-(isopropylamino)propyl)-3-(2,6-xylyl)urea
SCHEMBL636093
DTXSID50868319
Q27263709
1-(2,6-dimethylphenyl)-3-{3-[(propan-2-yl)amino]propyl}urea

Research Excerpts

Overview

Recainam is a novel class I antiarrhythmic agent. Its electrophysiologic effects in cardiac muscle are poorly defined. Recainam hydrochloride is a newly synthesized propylurea compound.

ExcerptReferenceRelevance
"Recainam is a new antiarrhythmic agent with class Ic properties. "( Electrophysiologic effects and antiarrhythmic efficacy of recainam in patients with supraventricular tachycardia.
Campbell, RW; McComb, JM; Tai, YT, 1991
)
1.97
"Recainam is a novel class I antiarrhythmic agent with electrophysiologic characteristics of all three subclasses. "( The absolute bioavailability and dose proportionality of intravenous and oral dosage regimens of recainam.
Cevallos, WH; Chiang, ST; Conrad, KA; Latts, JR; Troy, SM, 1991
)
1.94
"Recainam (Wy 42,362) is a new antiarrhythmic agent undergoing clinical evaluation, but its electrophysiologic effects in cardiac muscle are poorly defined. "( Electrophysiologic effects of a new antiarrhythmic agent, recainam, on isolated canine and rabbit myocardial fibers.
Kamiya, K; Kato, R; Singh, BN; Takikawa, R, 1988
)
1.96
"Recainam hydrochloride is a newly synthesized propylurea compound demonstrating potent antidysrhythmic effects. "( The disposition of recainam hydrochloride during and after intravenous loading and maintenance infusion in cardiac patients.
Anastasiou-Nana, MI; Anderson, JL; Capuzzi, DM; Hampton, EM; Nanas, JN; Nappi, JM, 1987
)
2.04

Pharmacokinetics

Recainam pharmacokinetic parameters were determined with a least-squares regression program. The plasma Cmax and AUC of recainam were virtually identical after single or multiple (21 day) oral doses in dogs.

ExcerptReferenceRelevance
" The plasma Cmax and AUC of recainam were virtually identical after single or multiple (21 day) oral doses in dogs."( Species differences in the pharmacokinetics of recainam, a new anti-arrhythmic drug.
Cayen, MN; Kimmel, HB; Scatina, JA; Sisenwine, SF; Troy, SM; Weinstein, V, 1990
)
0.83
" After a pharmacokinetic evaluation, efficacy was confirmed in a double-blind, crossover protocol."( Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias.
Capuzzi, DM; Davies, RF; Echt, DS; Funck-Brentano, C; Lee, JT; Lineberry, MD; Roden, DM; Woosley, RL, 1989
)
1.72
" Recainam pharmacokinetic parameters of apparent volume of distribution (Varea/F), apparent clearance (CL/F), elimination rate constant (ke), absorption rate constant (ka), lag-time (tlag), time to peak (tmax), and maximum concentration (Cmax) were determined with a least-squares regression program."( Effects of renal function on recainam pharmacokinetics and pharmacodynamics.
Charland, SL; Cheng, JW; Goldfarb, S; Spinler, SA, 1995
)
1.49
"05), Cmax (3."( Effects of renal function on recainam pharmacokinetics and pharmacodynamics.
Charland, SL; Cheng, JW; Goldfarb, S; Spinler, SA, 1995
)
0.58
" Further studies are required to fully characterize the pharmacodynamic profile of recainam."( Effects of renal function on recainam pharmacokinetics and pharmacodynamics.
Charland, SL; Cheng, JW; Goldfarb, S; Spinler, SA, 1995
)
0.81
" A 2-compartment pharmacokinetic model was used to analyze the data."( Antiarrhythmic and pharmacokinetic evaluation of intravenous recainam in patients with frequent ventricular premature complexes and unsustained ventricular tachycardia.
Anderson, JL; de Vane, PJ; Myerburg, RJ; Reddy, CP; Waxman, HL, 1993
)
0.53
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
" The authors evaluated the absolute bioavailability and dose proportionality of three oral doses and two 2-stage intravenous (IV) infusion doses."( The absolute bioavailability and dose proportionality of intravenous and oral dosage regimens of recainam.
Cevallos, WH; Chiang, ST; Conrad, KA; Latts, JR; Troy, SM, 1991
)
0.5
" Bioavailability was virtually complete in monkeys and dogs, 67 per cent in man and 51 per cent in rats."( Species differences in the pharmacokinetics of recainam, a new anti-arrhythmic drug.
Cayen, MN; Kimmel, HB; Scatina, JA; Sisenwine, SF; Troy, SM; Weinstein, V, 1990
)
0.54
" Recainam pharmacokinetic parameters of apparent volume of distribution (Varea/F), apparent clearance (CL/F), elimination rate constant (ke), absorption rate constant (ka), lag-time (tlag), time to peak (tmax), and maximum concentration (Cmax) were determined with a least-squares regression program."( Effects of renal function on recainam pharmacokinetics and pharmacodynamics.
Charland, SL; Cheng, JW; Goldfarb, S; Spinler, SA, 1995
)
1.49
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" No significant differences were found in any of the pharmacokinetic parameters between the two IV dosage regimens."( The absolute bioavailability and dose proportionality of intravenous and oral dosage regimens of recainam.
Cevallos, WH; Chiang, ST; Conrad, KA; Latts, JR; Troy, SM, 1991
)
0.5
" Dosage was increased stepwise every 48 to 72 hours until arrhythmia suppression, side effects, or a predetermined maximal dosage occurred."( Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias.
Capuzzi, DM; Davies, RF; Echt, DS; Funck-Brentano, C; Lee, JT; Lineberry, MD; Roden, DM; Woosley, RL, 1989
)
1.72
"Recainam dosing adjustment is required in renal impairment."( Effects of renal function on recainam pharmacokinetics and pharmacodynamics.
Charland, SL; Cheng, JW; Goldfarb, S; Spinler, SA, 1995
)
2.03
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540230Dose normalised AUC in rat after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID540232Dose normalised AUC in monkey after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540231Dose normalised AUC in dog after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540233Dose normalised AUC in human after po administration2005Xenobiotica; the fate of foreign compounds in biological systems, Feb, Volume: 35, Issue:2
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (48.15)18.7374
1990's7 (25.93)18.2507
2000's4 (14.81)29.6817
2010's3 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.55 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (25.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (3.57%)4.05%
Observational0 (0.00%)0.25%
Other20 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]